Top Markets
#1 Nesa Nesa +789.84%
#2 Cortex Cortex +68.84%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.81%
#4 Pons Pons +32.33%
#5 QuantixAI QuantixAI +23.56%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +17.69%
#8 Movement Movement +15.81%
#9 OpenEden OpenEden +15.59%
#10 Magma Finance Magma Finance +13.55%
Coin of the day
Nesa Nesa
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Prometheus Biosciences, Inc. Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDX
Classifica tra le azioni #3437
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Prezzo delle azioni
$199.92
Ultima sincronizzazione: 2023-06-15
Capitalizzazione di mercato
$5.39B
Variazione (1 giorno)
0.09%
Variazione (1 anno)
0.00%
Paese
US
Scambia Prometheus Biosciences, Inc. (RXDX)

Categoria

Healthcare
Storico del prezzo dell'azione per Prometheus Biosciences, Inc. (RXDX)
Prezzo di chiusura più alto: $199.05 il 2023-06-01

Prezzo di chiusura più basso: $20.65 il 2021-03-01
Storico del prezzo dell'azione di Prometheus Biosciences, Inc. dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2023 108.72%
2022 183.53%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.23 -12.55%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 7.33%
CH